Scarica l'app Stockscreener
1.05
0.00%
0.00
Dopo l'orario di chiusura:
1.06
0.01
+0.95%
Citius Oncology Inc Borsa (CTOR) Ultime notizie
Citius Oncology (CTOR) Ticks Higher: Shares Climb 2.39% to $1.07 Near Key ResistanceMomentum Stock Picks - siam.in
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTXR Stock Price, Quote & Chart - ChartMill
Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK
Citius Pharma CEO to speak at two New York conferences - Stock Titan
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire
Citius Oncology (CTOR) Slips 1.86% to $0.78 as Shares Press Against Key Support ZoneBPI Bull Confirmed - dars.gov.et
CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan
Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn
Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus
Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn
Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance
Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia
Citius Oncology (CTOR) Institutional Ownership 2026 $CTOR - MarketBeat
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart
Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart
Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade
Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn
Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia
People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa
Citius Oncology adds independent director to expanded board - TipRanks
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday - MarketBeat
Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
CTOR Q2 2026 Earnings: Deep EPS Miss Highlights Development-Stage Cash Burn ChallengesDividend Earnings Report - vinanet.vn
Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ
LYMPHIR orders rise 78% QoQ as Citius Oncology expands market access for CTCL treatment. - Pluang
Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks
Citius Oncology reports strong LYMPHIR commercial momentum - TipRanks
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - PR Newswire
Citius Oncology (CTOR) Adds 3.22% as Shares Hold Above $0.56 SupportEarnings Quality Factor - careplusvn.com
CTOR|Citius Oncology Inc|Price:0.654|Chg%:+0.062 - TradingKey
CTOR Q2 2026 Earnings: Significant EPS Miss Highlights Ongoing Development StageNon-GAAP Earnings - vinanet.vn
Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.18%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):